Literature DB >> 27614103

Nonalcoholic steatohepatitis is associated with a state of betaine-insufficiency.

Silvia Sookoian1, Puneet Puri2, Gustavo O Castaño3, Romina Scian1,4, Faridodin Mirshahi2, Arun J Sanyal2, Carlos J Pirola4.   

Abstract

BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) develops from a complex process, which includes changes in the liver methylome. Betaine plays a pivotal role in the regulation of methylogenesis. We performed a two-stage case-control study, which included patients with biopsy-proven NAFLD to explore circulating levels of betaine and its association with the histological spectrum. We also explored the association between a missense rs1805074, p.Ser646Pro variant in DMGDH (dimethylglycine dehydrogenase mitochondrial) and NAFLD severity (n=390).
RESULTS: In the discovery phase (n=48), betaine levels were associated with the disease severity (P=.0030), including liver inflammation (Spearman R:-0.51, P=.001), ballooning degeneration (R: -0.50, P=.01) and fibrosis (R: -0.54, P=.0008). Betaine levels were significantly decreased in nonalcoholic steatohepatitis (NASH) in comparison with nonalcoholic fatty liver (NAFL). Further replication (n=51) showed that betaine levels were associated with advanced NAFLD (P=.0085), and patients with NASH had a 1.26-fold decrease in betaine levels compared with those with NAFL. The rs1805074 was significantly associated with the disease severity (P=.011).
CONCLUSION: NAFLD severity is associated with a state of betaine-insufficiency.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  DNA methylation; betaine; biomarkers; dimethylglycine dehydrogenase mitochondrial; epigenetics; fibrosis; genetics; inflammation; metabolomics; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis

Mesh:

Substances:

Year:  2016        PMID: 27614103     DOI: 10.1111/liv.13249

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  21 in total

1.  mRNA-Sequencing Identifies Liver as a Potential Target Organ for Triphenyl Phosphate in Embryonic Zebrafish.

Authors:  Aalekhya Reddam; Constance A Mitchell; Subham Dasgupta; Jay S Kirkwood; Alyssa Vollaro; Manhoi Hur; David C Volz
Journal:  Toxicol Sci       Date:  2019-07-31       Impact factor: 4.849

2.  Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.

Authors:  Cyrielle Caussy; Veeral H Ajmera; Puneet Puri; Cynthia Li-Shin Hsu; Shirin Bassirian; Mania Mgdsyan; Seema Singh; Claire Faulkner; Mark A Valasek; Emily Rizo; Lisa Richards; David A Brenner; Claude B Sirlin; Arun J Sanyal; Rohit Loomba
Journal:  Gut       Date:  2018-12-19       Impact factor: 23.059

3.  A panel of biomarkers in the prediction for early allograft dysfunction and mortality after living donor liver transplantation.

Authors:  Hsin-I Tsai; Chi-Jen Lo; Chao-Wei Lee; Jr-Rung Lin; Wei-Chen Lee; Hung-Yao Ho; Chia-Yi Tsai; Mei-Ling Cheng; Huang-Ping Yu
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

4.  Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD.

Authors:  Cyrielle Caussy; Cynthia Hsu; Min-Tzu Lo; Amy Liu; Ricki Bettencourt; Veeral H Ajmera; Shirin Bassirian; Jonathan Hooker; Ethan Sy; Lisa Richards; Nicholas Schork; Bernd Schnabl; David A Brenner; Claude B Sirlin; Chi-Hua Chen; Rohit Loomba
Journal:  Hepatology       Date:  2018-05-20       Impact factor: 17.425

Review 5.  Molecular pathways of nonalcoholic fatty liver disease development and progression.

Authors:  Fernando Bessone; María Valeria Razori; Marcelo G Roma
Journal:  Cell Mol Life Sci       Date:  2018-10-20       Impact factor: 9.261

Review 6.  Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.

Authors:  Mojgan Masoodi; Amalia Gastaldelli; Tuulia Hyötyläinen; Enara Arretxe; Cristina Alonso; Melania Gaggini; Julia Brosnan; Quentin M Anstee; Oscar Millet; Pablo Ortiz; Jose M Mato; Jean-Francois Dufour; Matej Orešič
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-10       Impact factor: 46.802

7.  Impact on cardiometabolic risk of a weight loss intervention with higher protein from lean red meat: Combined results of 2 randomized controlled trials in obese middle-aged and older adults.

Authors:  Kathryn N Porter Starr; Margery A Connelly; Melissa C Orenduff; Shelley R McDonald; Richard Sloane; Kim M Huffman; William E Kraus; Connie W Bales
Journal:  J Clin Lipidol       Date:  2019-10-02       Impact factor: 5.365

8.  In ovo injection of betaine alleviates corticosterone-induced fatty liver in chickens through epigenetic modifications.

Authors:  Yun Hu; Qinwei Sun; Jie Liu; Yimin Jia; Demin Cai; Abdulrahman A Idriss; Nagmeldin A Omer; Ruqian Zhao
Journal:  Sci Rep       Date:  2017-01-06       Impact factor: 4.379

Review 9.  Beneficial Effects of Betaine: A Comprehensive Review.

Authors:  Madan Kumar Arumugam; Matthew C Paal; Terrence M Donohue; Murali Ganesan; Natalia A Osna; Kusum K Kharbanda
Journal:  Biology (Basel)       Date:  2021-05-22

10.  Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes.

Authors:  P León-Mimila; H Villamil-Ramírez; X S Li; D M Shih; S T Hui; E Ocampo-Medina; B López-Contreras; S Morán-Ramos; M Olivares-Arevalo; P Grandini-Rosales; L Macías-Kauffer; I González-González; R Hernández-Pando; F Gómez-Pérez; F Campos-Pérez; C Aguilar-Salinas; E Larrieta-Carrasco; T Villarreal-Molina; Z Wang; A J Lusis; S L Hazen; A Huertas-Vazquez; S Canizales-Quinteros
Journal:  Diabetes Metab       Date:  2020-08-10       Impact factor: 6.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.